| Participation in European-level policy and regulatory discussions affecting access to medicines for rare and systemic autoimmune diseases. Patient input and advocacy in consultations related to HTA, reimbursement frameworks, and access pathways. Collaboration with European patient platforms and alliances to convey patient perspectives on unmet needs, access delays, and equity in pricing and reimbursement decisions. | Reumatisk
> Sjögrens syndrom | Regulatorisk partnerskap
> Delta i vurderinger av medisinsk teknologi (HTA) og refusjonsgjennomganger | We do not communicate with patients directly | International | Regularly | 119025245981 |
| For the authorisation of medicinal products for rare diseases. | Endokrin
> Binyrebark- og hypofyselidelser | Regulatorisk partnerskap
> Bidra til innsendinger for markedsføringstillatelse | 100 | National | Rarely | 119052076100 |
| We are engaged in formal consultation processes. | Endokrin
> Diabetes (både type 1 og type 2) | Regulatorisk partnerskap
> Delta/fasilitere møter med beslutningstakere/regulatorer | Do not know | National | Rarely | 119035824614 |
| Advisory board of Swissmedic. | Kreft
> Kreft: lunge | Regulatorisk partnerskap
> Delta/fasilitere møter med beslutningstakere/regulatorer | 1 000 | National | Sometimes | 119061399060 |
| Participation in European-level policy and regulatory discussions affecting access to medicines for rare and systemic autoimmune diseases. Patient input and advocacy in consultations related to HTA, reimbursement frameworks, and access pathways. Collaboration with European patient platforms and alliances to convey patient perspectives on unmet needs, access delays, and equity in pricing and reimbursement decisions. | Reumatisk
> Sjögrens syndrom | Regulatorisk partnerskap
> Med andre helseadvokater | We do not communicate with patients directly | International | Regularly | 119025245981 |
| This has been achieved, for example, through the submission of concerns regarding access to therapies via umbrella organisations such as ProRaris, as well as through targeted engagement and formal submissions to relevant healthcare stakeholders. | Hud
> Angioødem | Regulatorisk partnerskap
> Med andre helseadvokater | 100 | National | Sometimes | 119052980204 |
| Via our umbrella organisation HOPOS [Hemato-Onkologische Patientenorganisationen Schweiz - Swiss Umbrella Organisation of Haemato-Oncological Patient Organisations]. | Kreft
> Kreft: blod | Regulatorisk partnerskap
> Med andre helseadvokater | 1 000 | National | Rarely | 119077844806 |
| To advocate for the establishment of an information policy directed at local authorities. | Kreft
> Kreft: prostata | Påvirkning av politikk og lovgivning
> Påvirk helsepolitikk og lovgivning | 100 | Regional | Sometimes | 115056429435 |
| Participation in European-level policy and regulatory discussions affecting access to medicines for rare and systemic autoimmune diseases. | Reumatisk
> Sjögrens syndrom | Påvirkning av politikk og lovgivning
> Påvirk helsepolitikk og lovgivning | We do not communicate with patients directly | International | Regularly | 119025245981 |
| Legislative adaptation through ongoing communication. | Sjelden
> Sjeldne sykdommer: barn/unge | Påvirkning av politikk og lovgivning
> Påvirk helsepolitikk og lovgivning | 1 000 | National | Sometimes | 119035891744 |
| Consultation on legislative drafts, and specific requests for assistance — whether material, structural, or socio-economic in nature. | Pasientopplæring
> Pasientopplæring | Påvirkning av politikk og lovgivning
> Påvirk helsepolitikk og lovgivning | 100 | National | Sometimes | 119035955624 |
| The Swiss Cancer Plan, in collaboration with Oncosuisse and the BAG [Bundesamt für Gesundheit – Federal Office of Public Health]. | Kreft
> Kreft: prostata | Påvirkning av politikk og lovgivning
> Påvirk helsepolitikk og lovgivning | 1 000 | National | Regularly | 119044110604 |
| Advocacy representation in relation to the new care legislation. | Nevrodegenerativ
> Alzheimers | Påvirkning av politikk og lovgivning
> Påvirk helsepolitikk og lovgivning | 100 000 | National | Regularly | 119044141359 |
| Consultation on legislative drafts, and specific requests for assistance — whether material, structural, or socio-economic in nature. | Pasientopplæring
> Pasientopplæring | Påvirkning av politikk og lovgivning
> Bidra til utarbeidelse av folkehelseregelverket | 100 | National | Sometimes | 119035955624 |
| Advocacy representation in relation to the new care legislation. | Nevrodegenerativ
> Alzheimers | Påvirkning av politikk og lovgivning
> Bidra til utarbeidelse av folkehelseregelverket | 100 000 | National | Regularly | 119044141359 |
| Support with formal cost-approval (reimbursement authorisation) applications and with newly introduced restrictions on treatment options. | Kardiovaskulær
> Familiær hyperkolesterolemi (FH) | Påvirkning av politikk og lovgivning
> Håndtering av barrierer/anomalier i medisinsk behandling | 100 | National | Sometimes | 119072887138 |
| Participation in European-level policy and regulatory discussions affecting access to medicines for rare and systemic autoimmune diseases. Patient input and advocacy in consultations related to HTA, reimbursement frameworks, and access pathways. Collaboration with European patient platforms and alliances to convey patient perspectives on unmet needs, access delays, and equity in pricing and reimbursement decisions. | Reumatisk
> Sjögrens syndrom | Prising og tilgjengelighetsadvokatur
> Gå inn for rettferdig medisinprising | We do not communicate with patients directly | International | Regularly | 119025245981 |
| We work to ensure that effective medicines are available to patients in a fair and timely way, and we explain how pricing and reimbursement decisions directly affect patients and their families in real life. | Kreft
> Kreft: lunge | Prising og tilgjengelighetsadvokatur
> Gå inn for rettferdig medisinprising | We do not communicate with patients directly | International | Sometimes | 119058458189 |
| Support with reimbursement approvals. | Kardiovaskulær
> Familiær hyperkolesterolemi (FH) | Prising og tilgjengelighetsadvokatur
> Arbeide for inkludering av produkt i refusjonslister/nasjonale formularer | 100 | National | Sometimes | 119072887138 |
| Primarily through public appeals, media coverage, and similar channels [on issues of drug pricing]. | HIV
> HIV | Prising og tilgjengelighetsadvokatur
> Engasjere seg i bevissthetskampanjer | 5 000 | National | Rarely | 119035314201 |
| Assisting a family in accessing a medication covered by their insurance. | Nevrologisk
> Nevrofibromatose (NF) | Forbedrer tilgangsveier
> Legge til rette for rettferdig tilgang til medisiner/helsetjenester | 100 | Regional | Rarely | 115023088362 |
| This has been achieved, for example, through the submission of concerns regarding access to therapies via umbrella organisations such as ProRaris, as well as through targeted engagement and formal submissions to relevant healthcare stakeholders. | Hud
> Angioødem | Forbedrer tilgangsveier
> Legge til rette for rettferdig tilgang til medisiner/helsetjenester | 100 | National | Sometimes | 119052980204 |
| We work to ensure that effective medicines are available to patients in a fair and timely way, and we explain how pricing and reimbursement decisions directly affect patients and their families in real life. | Kreft
> Kreft: lunge | Forbedrer tilgangsveier
> Legge til rette for rettferdig tilgang til medisiner/helsetjenester | We do not communicate with patients directly | International | Sometimes | 119058458189 |
| Participation in European-level policy and regulatory discussions affecting access to medicines for rare and systemic autoimmune diseases. Patient input and advocacy in consultations related to HTA, reimbursement frameworks, and access pathways. Collaboration with European patient platforms and alliances to convey patient perspectives on unmet needs, access delays, and equity in pricing and reimbursement decisions. | Reumatisk
> Sjögrens syndrom | Forbedrer tilgangsveier
> Forbedring av tilgang til sjeldne/ultrasjelne terapier | We do not communicate with patients directly | International | Regularly | 119025245981 |
| For the authorisation of medicinal products for rare diseases. | Endokrin
> Binyrebark- og hypofyselidelser | Forbedrer tilgangsveier
> Forbedring av tilgang til sjeldne/ultrasjelne terapier | 100 | National | Rarely | 119052076100 |
| ... Collaboration with European patient platforms and alliances to convey patient perspectives on unmet needs, access delays, and equity in pricing and reimbursement decisions. | Reumatisk
> Sjögrens syndrom | Evidensbasert pasientinnspill
> Bruk pasientinnsikt til å informere beslutninger | We do not communicate with patients directly | International | Regularly | 119025245981 |
| We speak up to make sure patients' views are properly taken into account when decisions are made about access to new treatments, their cost, and their value. | Kreft
> Kreft: lunge | Evidensbasert pasientinnspill
> Bruk pasientinnsikt til å informere beslutninger | We do not communicate with patients directly | International | Sometimes | 119058458189 |
| We speak up to make sure patients' views are properly taken into account when decisions are made about access to new treatments, their cost, and their value. | Kreft
> Kreft: lunge | Evidensbasert pasientinnspill
> Bruk pasientinnsikt til å informere beslutninger | We do not communicate with patients directly | International | Sometimes | 119058458189 |
| This has been achieved, for example, through the submission of concerns regarding access to therapies via umbrella organisations such as ProRaris, as well as through targeted engagement and formal submissions to relevant healthcare stakeholders. | Hud
> Angioødem | Evidensbasert pasientinnspill
> Oversett bevis og innsikt til politikkinnspill | 100 | National | Sometimes | 119052980204 |
| Participation in the RDA [Research Data Alliance]-Forum / CTA [Clinical Trial Authorisation] activities. | Reumatisk
> Sklerodermi | Diagnose og medisinlevering
> Samarbeid om utforming av kliniske studier | 100 | National | Rarely | 119056569513 |
| Through physicians, hospitals, and participation in PPI [Patient and Public Involvement] meetings. | Kreft
> Kreft: barn / unge | Institusjonell styring
> Arbeide effektivt i nettverk med flere interessenter | 100 | National | Sometimes | 115032067078 |
| The Swiss Cancer Plan, in collaboration with Oncosuisse and the BAG [Bundesamt für Gesundheit – Federal Office of Public Health]. | Kreft
> Kreft: prostata | Institusjonell styring
> Arbeide effektivt i nettverk med flere interessenter | 1 000 | National | Regularly | 119044110604 |
| We are a non-profit (ZEWO [Zentralstelle für Wohlfahrtsunternehmen - Central Office for Welfare Organisations]-certified) organisation. | Psykisk helse
> Depresjon | Institusjonell styring
> Opprettholde formell status som allmennyttig eller veldedig enhet | 1 000 | Regional | No | 119063159875 |
| Support for obtaining AI [Assurance Invalidité – Disability Insurance]. | Synshemming
> Synshemming | Ivaretakelse av pasientrettigheter/forbedring av livskvalitet
> Beskytte/forbedre pasientopplevelsen | 100 | Regional | Sometimes | 114996630534 |
interaksjoner
handlinger & påvirkning
7 omtaler
